LAS VEGAS, Aug. 25 Cord Blood America, Inc. (http://www.cordblood-america.com) (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, today announced that CEO Matt Schissler was interviewed recently by Tom Allinder of InBoundMarketingPR.
During the course of the interview, Mr. Schissler discussed contents of recent financially related news releases - retirement of the $1.1 million debt obligation with JMJ Financial on 5 August, 2010 and details from the 18 August, 2010 news release detailing the company's quarterly earnings. Mr. Schissler also discusses recent news that a federal judge temporarily blocked the Obama administration Monday from using federal dollars to fund expanded human embryonic stem cell research and how the news impacts Cord Blood America. The interview is accessible at http://inboundmarketingpr.com/clients/cord-blood-america/bid/45397/Interview-with-Matt-Schissler-CEO-of-Cord-Blood-America
About Cord Blood America
Cord Blood America is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc., visit our website at http://www.corcell.com/. For investor information, visit http://www.cordblood-america.com/.
Some statements made in this press release are forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We use words such as "anticipate," "believe," "expect,'' "future," "intend," "plan," and similar expressions to identify forward-looking statements. These statements including those related to the growth of the industry, new stem cell treatments, and the Cord Blood America's performance, are only predictions and are subject to certain risks, uncertainties and assumptions. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.
CONTACT: Paul Knopick E & E Communications 949/707-5365 email@example.com
SOURCE Cord Blood America, Inc.